Local Recurrence Rates of Skin Tumors After Resection With Complete Circumferential Peripheral and Deep Margin Assessment-Identification of High-Risk Entities

被引:14
|
作者
Kofler, Lukas [1 ]
Breuninger, Helmut [1 ]
Schulz, Claudia [1 ]
Haefner, Hans-Martin [1 ]
Kofler, Katrin [1 ]
机构
[1] Eberhard Karls Univ Tubingen, Dept Dermatol, Liebermeisterstr 25, D-72076 Tubingen, Germany
关键词
D O I
10.1097/DSS.0000000000002431
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
BACKGROUND The local recurrence rates of malignant skin tumors after micrographic controlled surgery using complete circumferential peripheral and deep margin assessment (CCPDMA) are reported to be low. However, in daily practice, tumor entities with a significantly higher recurrence rate are found. OBJECTIVE The aim of the investigation was to identify these high-risk tumors to develop approaches for risk stratification. PATIENTS AND METHODS We included different malignant tumors that were surgically treated and examined with CCPDMA using paraffin sections and H&E staining. Re-excisions were performed until the tumor was completely removed. RESULTS Ninety-nine thousand three hundred seventy-two tumors were included in the study; the follow-up period was 4 years (median). Eight tumor entities were identified as high-risk entities, showing a significantly higher local recurrence rate of over 20%: desmoplastic squamous cell carcinoma, desmoplastic melanoma, Merkel cell carcinoma, microcystic adnexal carcinoma, pleomorphic sarcoma, liposarcoma as well as angiosarcoma, and extramammary Paget's disease. CONCLUSION Complete circumferential peripheral and deep margin assessment allows complete control of the resection margins and enables skin-sparing resections with low recurrence rates for basal cell carcinomas, nondesmoplastic squamous cell carcinomas, lentiginous melanomas, and dermatofibrosarcoma protuberans. However, other tumors show significantly higher recurrence rates and therefore need to be classified as high-risk tumors.
引用
收藏
页码:e31 / e36
页数:6
相关论文
共 21 条
  • [21] Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: New recurrence-free survival results from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial at three-year median follow-up.
    Eggermont, Alexander M.
    Blank, Christian U.
    Mandala, Mario
    Long, Georgina V.
    Atkinson, Victoria
    Dalle, Stephane
    Haydon, Andrew Mark
    Meshcheryakov, Andrey
    Khattak, Muhammad
    Carlino, Matteo S.
    Sandhu, Shahneen Kaur
    Puig, Susana
    Ascierto, Paolo Antonio
    Christopher, Alexander
    Van Akkooi, Jonathan
    Krepler, Clemens
    Ibrahim, Nageatte
    Marreaud, Sandrine
    Kicinski, Michal
    Suciu, Stefan
    Robert, Caroline
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)